Heat Shock Protein 90 Involvement in the Development of Idiopathic Epiretinal Membranes.


Journal

Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701

Informations de publication

Date de publication:
01 07 2020
Historique:
entrez: 28 7 2020
pubmed: 28 7 2020
medline: 2 1 2021
Statut: ppublish

Résumé

This work was aimed to further characterize cells of idiopathic epiretinal membranes (iERMs). We wanted to determine the contribution of 90-kDa heat shock protein (HSP90) to sustain the transforming growth factor-β (TGF-β)-mediated signal transduction pathway in iERM. Immunofluorescence and confocal microscopy were carried out on deplasticized sections from 36 epiretinal membranes processed for electron microscopy and on frozen sections from five additional samples with antibodies against α-smooth muscle actin (αSMA), vimentin, glial fibrillary acidic protein (GFAP), SMAD2, HSP90α, type-II TGF-β1 receptor (TβRII), type-I collagen, and type-IV collagen. In addition, Müller MIO-M1 cells were transfected with HSP90 and challenged with TGF-β1. Double and triple labeling experiments showed that a variable number of TβRII+ cells were present in 94.1% of tested iERMs and they were mostly GFAP-/αSMA+/vimentin+/HSP90α+. In almost half of the cases these cells contained type-I collagen, suggesting their involvement in matrix deposition. HSP90 overexpressing MIO-M1 cells challenged with TGF-β1 showed increased levels of TβRII, SMAD2, SMAD3, and phosphor-SMAD2. Nuclear SMAD2 staining could be observed in HSP90α+ cells on frozen sections of iERMs. Cells in iERMs that express TβRII are also HSP90α+ and show the antigenic profile of myofibroblast-like cells as they are GFAP-/αSMA+/vimentin+. HSP90α-overexpressing MIO-M1 cells challenged with TGF-β1 showed an increased activation of the SMAD pathway implying that HSP90α might play a role in sustaining the TGF-β1-induced fibrotic response of iERM cells.

Identifiants

pubmed: 32716502
pii: 2770509
doi: 10.1167/iovs.61.8.34
pmc: PMC7425702
doi:

Substances chimiques

HSP90 Heat-Shock Proteins 0
Smad Proteins 0
Transforming Growth Factor beta 0
Transforming Growth Factor beta1 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

34

Références

Am J Physiol Lung Cell Mol Physiol. 2017 Dec 1;313(6):L1006-L1015
pubmed: 28860147
Retina. 2014 May;34(5):897-906
pubmed: 24077090
Invest Ophthalmol Vis Sci. 2011 Oct 03;52(11):7822-34
pubmed: 21900375
Ger J Ophthalmol. 1993 Feb;2(1):28-31
pubmed: 7679595
Br J Ophthalmol. 1985 Nov;69(11):810-23
pubmed: 4063247
Trans Am Ophthalmol Soc. 1994;92:403-25; discussion 425-30
pubmed: 7886875
J Pharmacol Exp Ther. 2009 Jul;330(1):276-82
pubmed: 19329756
Front Pharmacol. 2017 Jul 14;8:461
pubmed: 28769795
Lab Invest. 2012 Nov;92(11):1583-96
pubmed: 22964853
Acta Ophthalmol (Copenh). 1991 Aug;69(4):466-71
pubmed: 1721480
Neuropathol Appl Neurobiol. 2008 Oct;34(5):532-46
pubmed: 18005096
Nat Rev Nephrol. 2016 Jun;12(6):325-38
pubmed: 27108839
JCI Insight. 2017 Feb 23;2(4):e91454
pubmed: 28239659
Neural Regen Res. 2012 Jan 5;7(1):31-5
pubmed: 25806055
Vision Res. 2003 Apr;43(8):887-97
pubmed: 12668058
Retina. 2008 Apr;28(4):628-37
pubmed: 18398367
Invest Ophthalmol Vis Sci. 1995 Feb;36(2):391-405
pubmed: 7531185
J Am Soc Nephrol. 2016 Oct;27(10):3117-3128
pubmed: 26961347
Retina. 2013 Jan;33(1):77-88
pubmed: 22914684
FEBS Lett. 2004 Mar 26;562(1-3):11-5
pubmed: 15069952
Mol Vis. 2010 Nov 27;16:2511-23
pubmed: 21139996
Invest Ophthalmol Vis Sci. 2002 Mar;43(3):864-9
pubmed: 11867609
Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9244-9
pubmed: 18591668
Chem Biol Interact. 2018 Aug 25;292:76-83
pubmed: 30017632
Invest Ophthalmol Vis Sci. 2000 Jul;41(8):2336-42
pubmed: 10892881
Sci Transl Med. 2013 Jan 9;5(167):167sr1
pubmed: 23303606
FASEB J. 2014 Jan;28(1):131-42
pubmed: 24022401
Angiogenesis. 2012 Jun;15(2):187-97
pubmed: 22327338
Stem Cells. 2015 Mar;33(3):742-50
pubmed: 25504116
J Histochem Cytochem. 2009 Jun;57(6):577-86
pubmed: 19223297
J Histochem Cytochem. 2014 Aug;62(8):584-97
pubmed: 24850662
Sci Rep. 2018 May 23;8(1):8053
pubmed: 29795291
Invest Ophthalmol Vis Sci. 2010 May;51(5):2755-63
pubmed: 20042656
Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6506-14
pubmed: 26447986
PLoS One. 2015 Mar 19;10(3):e0119797
pubmed: 25790295
Exp Cell Res. 1997 May 25;233(1):169-86
pubmed: 9184086
Graefes Arch Clin Exp Ophthalmol. 2014 Dec;252(12):1887-94
pubmed: 25377434
J Clin Invest. 2011 Jan;121(1):277-87
pubmed: 21135509
Histopathology. 2011 May;58(6):953-65
pubmed: 21480957
Mol Vis. 2011;17:1794-805
pubmed: 21750605
Exp Eye Res. 2016 Jan;142:26-31
pubmed: 26675400
J Histochem Cytochem. 2020 Feb;68(2):149-162
pubmed: 31858878
Invest Ophthalmol Vis Sci. 1977 May;16(5):416-22
pubmed: 852943
Ophthalmology. 2016 Jan;123(1):P152-81
pubmed: 26578445
Mol Cell. 2000 Dec;6(6):1365-75
pubmed: 11163210
Ophthalmology. 1989 Jun;96(6):801-10
pubmed: 2662102
Sci Rep. 2019 Jan 24;9(1):673
pubmed: 30679596

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH